Traders should monitor Surrozen's stock for increased trading volume and potential downward price pressure as the company begins selling shares under this ATM program. The dilution from this offering, combined with the company's history of significant losses, presents a bearish fundamental outlook.
Price Chart
Executive Summary
Surrozen, Inc. has filed an S-3 shelf registration statement with the SEC, authorizing the potential issuance of up to $200 million in securities, including a specific $50 million ATM offering of common stock through TD Securities. This filing signals the company's intent to raise capital opportunistically, which will dilute existing shareholders. The offering proceeds will be used for general corporate purposes, including R&D, as the company continues to incur significant losses in its biotech development.
Key Financial Metrics
Key Facts
- Surrozen filed an S-3 shelf registration for up to $200 million in securities.
- A specific $50 million ATM offering of common stock is authorized through TD Securities (USA) LLC.
- The offering is an 'at-the-market' (ATM) program, allowing Surrozen to sell shares continuously at prevailing market prices.
- The company intends to use the net proceeds for working capital and general corporate purposes, including research and development.
- The company reported a net loss of $71.6 million for the three months ended September 30, 2025, indicating a continued need for capital.
Financial Impact
Up to $50 million in new capital, with significant dilution to existing shareholders.
Risk Factors
- Significant dilution for existing shareholders as new shares are issued.
- Downward pressure on the stock price due to continuous share sales in the open market.
- The company's ability to achieve profitability remains highly uncertain, as it is still in the pre-revenue, research and development phase.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-120016 |
| Document: srzn-ex1_2.htm | 0001193125-26-120016 |
| Document: srzn_exfilingfees.htm | 0001193125-26-120016 |
| Document: srzn-ex5_1.htm | 0001193125-26-120016 |
| Document: srzn-ex23_1.htm | 0001193125-26-120016 |
| Document: 0001193125-26-120016-index-headers.html | 0001193125-26-120016 |
| CONTEXT: 10-Q (2025-11-07) | 0001193125-25-272422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 7w ago | 25-NSE | $25.09 $20.68 | ▼ −17.58% | ▼ −16.66% | $29.65 (+18.17%) |
May 4, 2026 21w ago | Insider Cluster | $32.07 $24.71 | ▼ −22.95% | ▼ −28.59% | $29.65 (−7.55%) |
Mar 23, 2026 27w ago | S-3 | $25.00 $33.03 | ▼ −32.12% | ▼ −23.22% | $29.65 (−18.60%) |
Mar 23, 2026 27w ago | Press Release | $25.00 $33.03 | ▲ +32.12% | ▲ +23.22% | $29.65 (+18.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access